Ono Pharmaceutical Co., Ltd. (OPHLY) es una empresa que cotiza en bolsa en el Salud sector, operando dentro de la Drug Manufacturers - General industria. La empresa tiene su sede en Osaka, Japan. El CEO actual es Gyo Sagara.
OPHLY tiene fecha de IPO 2012-10-02, 3,853 empleados a tiempo completo, cotiza en el Other OTC, una capitalización de mercado de $7.53B.
Ono Pharmaceutical Co., Ltd. is a Japan-based pharmaceutical company headquartered in Osaka with a history dating back to 1717. The company develops, manufactures, and markets a diverse portfolio of prescription medications across oncology, cardiovascular, immunology, and other therapeutic areas, with leading products including OPDIVO for cancer treatment, FORXIGA for diabetes, ORENCIA for rheumatoid arthritis, and CORALAN for heart failure. Operating globally through its subsidiaries, Ono maintains a robust pipeline of drugs in development targeting a wide range of cancers, neurological disorders, autoimmune conditions, and other serious diseases. The company combines its heritage in pharmaceutical innovation with modern research capabilities to serve patients and healthcare systems worldwide.
